Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) shares shot up 1.4% during trading on Friday . The stock traded as high as $7.71 and last traded at $7.48, with a volume of 61,796 shares trading hands. The stock had previously closed at $7.38.

Several brokerages have commented on ADAP. Zacks Investment Research downgraded shares of Adaptimmune Therapeutics PLC – from a “hold” rating to a “sell” rating in a research report on Thursday. Leerink Swann restated a “buy” rating on shares of Adaptimmune Therapeutics PLC – in a research report on Sunday, April 24th. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $15.94.

The company’s market capitalization is $538.67 million. The stock has a 50-day moving average of $8.18 and a 200 day moving average of $8.63.

Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) last issued its quarterly earnings results on Monday, August 8th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.21) by $0.16. Analysts predict that Adaptimmune Therapeutics PLC – will post ($1.16) EPS for the current fiscal year.

In other Adaptimmune Therapeutics PLC – news, Director Charles Elliott Sigal acquired 45,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 18th. The stock was bought at an average cost of $1.53 per share, with a total value of $68,850.00. Following the acquisition, the director now owns 52,938 shares in the company, valued at $80,995.14. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Orbimed Advisors Llc acquired 1,712,400 shares of the business’s stock in a transaction that occurred on Tuesday, May 24th. The stock was acquired at an average cost of $10.42 per share, with a total value of $17,843,208.00. The disclosure for this purchase can be found here.

A hedge fund recently bought a new stake in Adaptimmune Therapeutics PLC – stock. Marshall Wace LLP acquired a new stake in Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 140,983 shares of the company’s stock, valued at approximately $1,700,000. Marshall Wace LLP owned about 0.20% of Adaptimmune Therapeutics PLC – as of its most recent SEC filing.

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.